A B S T R A C T We have examined the relative rates of uptake of several fatty acids into washed, human platelets by measuring incorporation into cellular phospholipids. In the presence of 15 uM fatty acid-free albumin and with radioactive fatty acid concentrations of 5-500 nM, esterification into phospholipid was linear with time and platelet concentration and saturable with respect to fatty acid concentration. Two distinct classes of uptake rate were observed. Arachidonate and 5,8,11,14,17-eicosapentaenoate exhibited high affinity, relatively rapid incorporation into platelet phospholipids at pH 6.5: apparent Michaelis constant (K.) = 30 nM, apparent maximum velocity (Vmax) = 28 pmol/min per 109 platelets. Two other eicosanoid precursors, 5,8,11-eicosatrienoate and 8,11,14-eicosatrienoate, exhibited the same Vmax, but Km of 85 and 60 nM, respectively. Under the same conditions, stearate, oleate, and linoleate were incorporated into phospholipids much less efficiently (Vmax -8 pmol/109 cells per min, apparent Km 2 170 nM). Qualitatively similar results were found at pH 7.4. Uptake of radiolabeled, rapid-uptake fatty acids was not diminished by the presence of excess, unlabeled, slow-uptake fatty acids. Thus, the specificity of this esterification system resembles that of the arachidonate-specific, long-chain acyl-CoA synthetase present in platelets. It may represent the expression in vivo of the synthetase, although the apparent affinity of the synthetase for fatty acid is much less. This esterification system probably represents the physiologic mechanism for platelet arachidonate uptake, whereby arachidonate is collected from plasma, despite the fact that its concentration is
INTRODUCTION
When human platelets are incubated with low levels of radiolabeled arachidonic acid (micromolar or less) in plasma or in buffer containing albumin, the label is readily esterified into platelet phospholipids (1, 2) . This occurs despite the huge excess in plasma of other fatty acids (3) and the presence in platelets of the arachidonate metabolizing enzymes, cyclooxygenase and 12-lipoxygenase. Another cyclooxygenase substrate, 8,11,14-eicosatrienoic acid (ETA),' is also readily esterified (1) . In contrast, tracer levels of prevalent plasma fatty acids, palmitate, stearate, oleate, and linoleate are esterified more slowly. Platelets, therefore, contain substantial amounts of these free fatty acids, but virtually no free arachidonate (4).
Wilson et al. (5) have recently described a longchain acyl-CoA synthetase in isolated platelet membranes that is specific for arachidonate and other eicosanoid (6) precursors (cyclooxygenase or lipoxygenase substrates). This activity is not inhibited by the nonprecursors, stearate, oleate, or linoleate, and therefore is a reasonable candidate for the esterification activity observed in intact platelets. In experiments designed to assess the physiological role of this enzyme, we have found that platelets in albumin-containing buffer exhibit remarkable affinity for uptake and esterification into phospholipids of arachidonate, 8,11,14-ETA, 5,8,11-ETA, and 5,8,11,14,17-eicosapen-taenoic acid (EPA), but not of stearate, oleate, or linoleate.
We report here the behavior of this high affinity system at low fatty acid concentrations (5-500 nM) and compare the substrate specificity of the system in intact platelets to that of the arachidonoyl-CoA synthetase in isolated membranes.
METHODS
Materials. 5,8,11-ETA and [1-`4C]5,8,11-ETA (17 uCi/ rmol) were synthesized as described (7) . ['4C]Stearic acid (47 ACi/Mmol), [9,10- Platelets were obtained from normal human volunteers who had abstained from aspirin for 2 wk or who had taken 1,300 mg of aspirin in the 24 h preceding phlebotomy. The cells were washed as described previously (8) . Platelets were resuspended to 109/ml in "pH 6.5 phosphate buffer" (26.2 mM sodium and 6.8 mM potassium phosphate, pH 6.5; 118 mM NaCl, 5.6 mM glucose) and kept at 23°C for up to 4 h before use. Incubations with fatty acids were done either in pH 6.5 phosphate buffer or in "pH 7.4 Tris buffer" (15.4 mM Tris-Cl, pH 7.4; 140 mM NaCl, 5.6 mM glucose).
Fatty acid uptake. Fatty acid uptake was assayed as radioactivity appearing in platelet phospholipids after incubation with radioactive fatty acids. The standard assay was performed at 37°C in 1.5 ml (total volume) of pH 6.5 phosphate buffer. The platelet concentration was 5 X 107/ml, the radioactive fatty acid concentration was from 5 to 500 nM. Fatty acid-free albumin was present at 1 mg/ml (15 ,uM) . In some experiments, 1 uM unlabeled fatty acids was included in reaction mixtures.
For each experiment, platelets (109/ml in pH 6.5 phosphate buffer) and the remainder of each reaction mixture were warmed to 37°C. Each reaction was started by adding platelets and vortexing the mixture gently, and was stopped by 1-min centrifugation in a microfuge (Eppendorf). Some reactions were stopped directly by extraction with chloroform/methanol, in the case of arachidonate uptake. Since similar results were obtained with both methods, the centrifugation method was used thereafter. The supernatant labeling medium was aspirated and the cell pellet was resuspended in 150 ul of H20, plus 1 ml of CHCl3/CH3OH/ concentrated HCl (50:50:0.3, vol/vol/vol). After the pellet was completely dispersed, the phases were split with 0. (10) . Long-chain acyl-CoA synthetase was assayed as described by Wilson et al. (5) .
RESULTS
Measurement of radiolabeled phospholipid synthesis was an accurate reflection of total fatty acid uptake. Under the conditions described here, measurement of radioactivity at the origin of a neutral-lipid TLC system (phospholipids) accounts quantitatively for uptake of fatty acid, in a manner indicative of a platelet enzymatic function.
(a) Platelet pellet-associated radioactivity. Over 90% of esterified radiolabeled fatty acid in extracted platelet pellets was present in phospholipids, as opposed to di-or triglycerides. Free fatty acid in the pellets amounted to 1% or less of the total fatty acid present in the labeling medium, so long as fatty acid-free albumin was present in large molar excess (not shown). Boiled platelet blanks exhibited no phospholipid synthesis whatsoever, but trapped amounts of free substrate equal to or greater than those in intact platelets. The free fatty acid was <15% of total pellet-associated radioactivity for eicosanoid precursors, and up to 30% for other fatty acids.
(b) Albumin was a necessary component of the reaction mixture. In its absence, from 3 to 25% of the labeled free fatty acid in the reaction medium was associated with the platelet pellet. This percentage varied among individual fatty acids, making local concentrations in the platelet membrane quite variable. It was therefore impossible to compare substrates for esterification in the absence of albumin.
(c) Removal of the unreacted labeling medium by centrifugation and aspiration was important because commercial supplies of radiolabeled fatty acids contain up to 5% impurities that migrate with phospholipids in our TLC system.
(d) The assay under standard conditions (described in Methods) was linear with time for .15 min at maximal fatty acid concentrations (Fig. 1) .
(e) The assay was linear with platelet concentration from 5 X 107/ml up to the physiological range ( Two classes of uptake behavior were distinguished. Fig. 3 shows the dependence of esterification of radiolabeled fatty acid on concentration of substrate. Arachidonate, EPA, 5,8,11-ETA, and 8,11,14-ETA constituted a "rapid-uptake" class. The "slow-uptake" group comprised stearate, oleate, and linoleate. When the data for Fig. 3 were plotted in double-reciprocal form, the difference in rates was readily seen to be due both to a greater apparent affinity for rapid-uptake fatty acids, and a higher apparent maximum velocity (Table I The data shown in Fig. 3 were replotted in double-reciprocal form to give apparent Km (column 1) and Vma. values (column 2) for each fatty acid at pH 6.5. Data for a pH 7.4 experiment were similarly treated. The ratio, apparent Vma./apparent Km (column 3) is an index of the relative efficiency with which the uptake system can esterify these fatty acids. Column 4 expresses these efficiencies compared with arachidonate (set to 100%).
uptake measurements were done at saturating label concentrations (.500 nM) for long periods of time, thereby obscuring the effect of the high affinity system. Platelets also contained a low affinity esterification system with relatively high capacity for phospholipid synthesis. In studies using much higher (50-300 gM) fatty acid concentrations, platelets have been shown to esterify oleate (11) and linoleate (12) into phospholipids with apparent Vma. -100 pmol/min per 109 platelets. The affinity for oleate and linoleate esterification observed in these studies was too low to contribute to the rates observed in Fig. 3 .
It might be argued that the low rates of uptake observed for radiolabeled, common fatty acids (stearate, oleate, and linoleate) were an artifact of dilution by endogenous pools of these fatty acids. However, at the platelet concentrations of the standard assay, 5 X 107/ ml, the cells could contribute only 50 nM or less to each reaction (4) . This could raise the apparent Km of the slow-uptake fatty acids only slightly, and it could not account for the diminished Vmax.
Slow-uptake fatty acids cannot compete with rapiduptake fatty acids for esterification. Table II shows the results of an experiment in which several unlabeled fatty acids were tested for their ability to inhibit the formation of radiolabeled phospholipid when present in 14-fold excess over radioactive substrate. It is clear that although 5, 8, 11 -ETA and arachidonate could compete for each other's uptake, oleate and linoleate could not inhibit the esterification of these fatty acids when present in 14-fold excess. Unlabeled 5,8,11-ETA was somewhat less effective as a competing fatty acid than arachidonate, presumably because it was less efficiently recognized by the uptake system (Table I) .
Similar results were found in every pair-wise combination tested. Thus, EPA and 8,11,14-ETA uptake were inhibited by arachidonate, but not by oleate, and stearate had no effect on phospholipid synthesis from rapid-uptake fatty acids (not shown). We conclude that slow-uptake fatty acids are not recognized by the esterification site for rapid-uptake substrates, although the converse may be true, since arachidonate inhibited linoleate uptake (Table II) .
Measurement of platelet arachidonate uptake from plasma. To assess the physiological role of the high affinity system, we assayed ['4C]arachidonoyl-phospholipid synthesis by platelets in plasma. Blood was collected from eight healthy volunteers after an overnight fast. Washed platelets and platelet-poor plasma were prepared from each blood sample. Radiolabeled arachidonate, 10-1,000 nM, was added to samples of plasma and allowed to equilibrate for 1 h. Platelets (5 X 107/ml) were then added back to each plasma sample and esterification was measured as described in Methods for standard assays. At 12-HETE and 15-HETE were not substratesfor the high affinity esterification system. Neutrophils (14) and macrophages (15) can incorporate products of Table IV . It is likely that the present results reflect the in vivo expression of the arachidonoyl-CoA synthetase. The apparent Km of the synthetase in vitro may be 200-fold higher because of nonspecific binding of fatty acid substrate to membranes and membrane proteins in the assay mixture that are not normally exposed in intact platelets. The small Vmax of esterification we measured in vivo, 150-fold lower than the Vmax of the synthetase, may be a function of less-than-optimal reaction conditions in intact cells (for example, CoA concentrations may be suboptimal intracellularly).
Another possible explanation for the disparity between in vivo and in vitro measurements is that high affinity arachidonate uptake reflects the presence of a specific carrier for arachidonate entry into platelets, distinct from the arachidonoyl-CoA synthetase, but with similar fatty acid specificity. This seems unlikely, since long-chain fatty acids can diffuse readily into and out of platelet membranes (12) . It is also unlikely that the rate-limiting step in arachidonoyl-phospholipid synthesis occurs at a step beyond formation of arachidonoyl-CoA, since total acyl-CoA levels in platelets are always exceedingly low ('-0.05 nmol/109 platelets; 5) .
Platelet esterification of arachidonate is relatively independent of albumin concentration. At fatty acid at 5-6 nmol/h per 109 platelets (80-100 pmol/ min/109 cells; 2); this turnover may be related to phospholipid remodeling. The reason that high affinity arachidonate esterification may be necessary in platelets is that to the extent that free arachidonate is generated in the process of altering the fatty acid composition of phospholipids, it must be collected by a specific esterification system. Otherwise this released arachidonate would be replaced by the more prevalent platelet and plasma free fatty acids.
Exogenous arachidonate at submicromolar concentrations apparently enters phospholipids not by de novo synthesis (acylation of glycerol phosphate) but via transacylation of lysophospholipids (Lands pathway). We have shown that phosphatidic acid in unstimulated platelets turns over with t1/2 2-4 min (80-300 pmol/min per 109 platelets; 19). Given this turnover rate, phosphatidate is never labeled with exogenous radioactive arachidonate enough to account for its accumulation in phospholipids (unpublished observation). The determinants of specificity for acyltransferase reactions are not known; presumably, the acyl-CoA synthetase cannot account for preferential transacylase incorporation of arachidonate. McKean et al. (20) have shown that platelets contain a lysophosphatidylcholine acyl transferase activity that prefers unsaturated acyl-CoA, but this activity lacks the absolute arachidonate specificity of the acyl CoA synthetase (20) .
The demand for acyl CoA in platelets, for de novo synthesis of phospholipids alone, is 160-600 pmol/min per 109 platelets (two times the phosphatidate synthetic rate). It is therefore clear that the high affinity uptake described here accounts for only a small portion of total fatty acid esterification. Nevertheless, an uptake system for arachidonate with very high affinity (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) nmol/109 platelets in <1 min [1, 21] ), thereby allowing production of thromboxane and 12-HETE.
